Kornhuber J, Bleich S, Wiltfang J, Maler M, Parsons CG, Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication, in J Neural Transm, vol. 106, n. 9-10, 1999, pp. 857–67, PMID10599868.
(DE) Jakovlev V, Achterrath-Tuckermann U, von Schlichtegroll A, Stroman F, Thiemer K, [General pharmacologic studies on the analgesic flupirtine], in Arzneimittelforschung, vol. 35, n. 1, 1985, pp. 44–55, PMID4039152.
(DE) [Centrally acting analgesic against fibromyalgia. The body's own pain control is activated], in MMW Fortschr Med, Suppl 2, maggio 2002, p. 85, PMID12070864.
(DE) Scheef W, Wolf-Gruber D, [Flupirtine in patients with cancer pain], in Arzneimittelforschung, vol. 35, n. 1, 1985, pp. 75–7, PMID3885963.
Riethmüller-Winzen H, Flupirtine in the treatment of post-operative pain, in Postgrad Med J, 63 Suppl 3, 1987, pp. 61–5, PMID3328853.
Schröder HC, Müller WE, Neuroprotective effect of flupirtine in prion disease, in Drugs Today, vol. 38, n. 1, gennaio 2002, pp. 49–58, PMID12532184.
Perovic S, Pergande G, Ushijima H, Kelve M, Forrest J, Müller WE, Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate, in Neurodegeneration, vol. 4, n. 4, dicembre 1995, pp. 369–74, PMID8846229.
Perovic S, Böhm M, Meesters E, Meinhardt A, Pergande G, Müller WE, Pharmacological intervention in age-associated brain disorders by Flupirtine: Alzheimer's and prion diseases, in Mech. Ageing Dev., vol. 101, n. 1-2, marzo 1998, pp. 1–19, PMID9593309.